[go: up one dir, main page]

Pereira, 2024 - Google Patents

Current principles for the establishment of the virological “cutoff points” in transfusion science and medicine: A short concise overview

Pereira, 2024

View PDF
Document ID
180095339745016261
Author
Pereira P
Publication year
Publication venue
Transfusion and Apheresis Science

External Links

Snippet

Establishing the virological cutoff point, during epidemics, such as the COVID-19 Pandemic, is crucially important as inadequate standardization and the false qualitative results, have enormous clinical and economic consequences when screening for SARS-CoV-2 …
Continue reading at www.trasci.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/345—Medical expert systems, neural networks or other automated diagnosis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/3431—Calculating a health index for the patient, e.g. for risk assessment
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • G06F19/366—Acquisition of data related to laboratory tests, e.g. special identifiers for examination containers
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G06Q50/24—Patient record management
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature

Similar Documents

Publication Publication Date Title
World Health Organization Framework for the evaluation of new tests for tuberculosis infection
Caturegli et al. Clinical validity of serum antibodies to SARS-CoV-2: a case–control study
Jennings et al. Recommended principles and practices for validating clinical molecular pathology tests
Lane et al. Screening strategies to identify sepsis in the prehospital setting: a validation study
Rifai Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics 8 e; South Asia edition; E-book
Hainrichson et al. A point-of-need platform for rapid measurement of a host-protein score that differentiates bacterial from viral infection: analytical evaluation
Fukuda et al. SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo
Newcomer et al. A primer on quantitative bias analysis with positive predictive values in research using electronic health data
Eyre et al. Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections
McLernon et al. Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts
Gollan et al. Generating an efficient version of the Edinburgh Postnatal Depression Scale in an urban obstetrical population
Doust et al. Guidance for the design and reporting of studies evaluating the clinical performance of tests for present or past SARS-CoV-2 infection
Köksal et al. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
Pereira et al. Evaluation of the measurement uncertainty in screening immunoassays in blood establishments: Computation of diagnostic accuracy models
Mustanski et al. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility
Futschik et al. Rapid antigen testing for SARS-CoV-2 by lateral flow assay: A field evaluation of self-and professional testing at UK community testing sites
World Health Organization Optimizing HIV testing algorithms: a generic verification protocol for selecting appropriate HIV serology assays and assessing the level of shared false reactivity: verification toolkit, November 2021
Knight et al. Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome
Hibberd Use and misuse of statistics for epidemiological studies of multiple sclerosis
Kolev et al. Rational development and application of biomarkers in the field of autoimmunity: a conceptual framework guiding clinicians and researchers
Howell et al. Validation of a novel point‐of‐care test for alanine aminotransferase measurement: A pilot cohort study
Pereira Current principles for the establishment of the virological “cutoff points” in transfusion science and medicine: A short concise overview
Gitau et al. High prevalence of liver fibrosis in patients with human immunodeficiency virus monoinfection and human immunodeficiency virus hepatitis-B co-infection as assessed by shear wave elastography: study at a teaching hospital in Kenya
Rifai Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics-E-Book: Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics-E-Book
Pereira et al. Spotlights on the trends in performance assessment of qualitative in vitro diagnostic medical devices in transfusion medicine